Related Experiment Video
Updated: Apr 20, 2026
06:15
Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
Published on: March 6, 2019
53.1K
Decision making in lung cancer – how applicable are the guidelines?
1Cancer Therapy Centre, Liverpool Hospital, Liverpool, New South Wales, Australia; South Western Sydney Clinical School, University of New South Wales, New South Wales, Australia; University of Western Sydney, New South Wales, Australia.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|December 4, 2014
Summary
Guideline adherence for lung cancer treatment is modest, particularly in older patients or those with comorbidities. Research is needed to improve guideline applicability for diverse patient populations.
Area of Science:
- Oncology
- Clinical Practice Guidelines
- Health Services Research
Background:
- Modelling radiotherapy demand relies on consistent guideline application.
- Lung cancer treatment involves complex multimodality decisions, often in patients with comorbidities.
- Existing studies show modest guideline adherence (44-52%) in lung cancer care.
Purpose of the Study:
- To highlight challenges in applying lung cancer clinical guidelines to the general patient population.
- To identify factors limiting guideline adherence.
- To emphasize the need for research to enhance guideline applicability.
Main Methods:
- Review of population studies on lung cancer treatment adherence.
- Analysis of factors influencing guideline application, including age, comorbidities, and sociodemographics.
- Examination of the mismatch between clinical trial populations and real-world lung cancer patients.
Main Results:
- Guideline treatment application decreases with increasing age and comorbidities.
- Sociodemographic factors like lower income and non-White race are associated with lower adherence.
- A significant barrier is the exclusion of older patients with comorbidities from clinical trials.
Conclusions:
- Lung cancer treatment guideline adherence is suboptimal and influenced by patient characteristics and systemic factors.
- The discrepancy between clinical trial participants and the general lung cancer population creates uncertainty regarding treatment benefits and toxicities.
- Further research is crucial to adapt guidelines for broader applicability, impacting radiotherapy demand modeling.